<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1188</article-id><article-id pub-id-type="doi">10.25208/vdv1188-2020-96-5-24-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Efficiency of phototherapy in patients with mycosis fungoides: preliminary results of a comparative non-randomized study</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность фототерапии у больных грибовидным микозом: предварительные результаты сравнительного нерандомизированного исследования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3805-8489</contrib-id><contrib-id contrib-id-type="spin">3604-6491</contrib-id><name-alternatives><name xml:lang="en"><surname>Karamova</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Карамова</surname><given-names>А. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., заведующий отделом дерматологии</p></bio><email>karamova@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="spin">8930-4073</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhilova</surname><given-names>M. B.</given-names></name><name xml:lang="ru"><surname>Жилова</surname><given-names>М. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., заведующий отделением физиотерапии</p></bio><email>zhilova@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2553-0484</contrib-id><contrib-id contrib-id-type="spin">9552-7850</contrib-id><name-alternatives><name xml:lang="en"><surname>Znamenskaya</surname><given-names>L. F.</given-names></name><name xml:lang="ru"><surname>Знаменская</surname><given-names>Л. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., ведущий научный сотрудник отдела дерматологии</p></bio><email>znaml@cnikvi.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3129-0050</contrib-id><contrib-id contrib-id-type="spin">8334-2890</contrib-id><name-alternatives><name xml:lang="en"><surname>Vorontsova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Воронцова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior researcher of department of dermatology</p></bio><bio xml:lang="ru"><p>Младший научный сотрудник отдела дерматологии</p></bio><email>nastasia08@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-12-14" publication-format="electronic"><day>14</day><month>12</month><year>2020</year></pub-date><volume>96</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>24</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2020-11-24"><day>24</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-12-01"><day>01</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Karamova A.E., Zhilova M.B., Znamenskaya L.F., Vorontsova A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Карамова А.Э., Жилова М.Б., Знаменская Л.Ф., Воронцова А.А.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Karamova A.E., Zhilova M.B., Znamenskaya L.F., Vorontsova A.A.</copyright-holder><copyright-holder xml:lang="ru">Карамова А.Э., Жилова М.Б., Знаменская Л.Ф., Воронцова А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/1188">https://vestnikdv.ru/jour/article/view/1188</self-uri><abstract xml:lang="en"><p><bold>Clinical reasoning.</bold> There is a need to optimize the use of UV-B-311 nm and PUVA-therapy in patients with mycosis fungoides — to determine the duration of the treatment regimen, the number of sessions per week, and ultraviolet irradiation regimen.</p> <p><bold>Goal of research.</bold> Evaluation of the effect of the type and duration phototherapy on efficacy in patients with mycosis fungoides.</p> <p><bold>Principle.</bold> A comparative, non-randomized study of the effectiveness of phototherapy in patients with mycosis fungoides in the early stages. Evaluation of the effectiveness of UV-B-311 nm and PUVA therapy was performed using the BSA index (area of skin lesions) and Modified Severity-Weighted Assessment Tool (mSWAT), as well as according to the criteria proposed by the International Society for Skin Lymphomas (ISCL), the European Organization for the Study and Cancer Treatment (EORTC) and United States Cutaneous Lymphoma Consortium (USCLC).</p> <p><bold>Results.</bold> The study included 14 patients with mycosis fungoides, 5 of whom received treatment with UV-B-311 nm, 9 — PUVA therapy. A strong correlation was found between the duration of UV-B-311 nm therapy with mSWAT delta (<italic>R</italic> = 0.90; <italic>p</italic> = 0.038) and BSA delta (<italic>R</italic> = 0.90; <italic>p</italic> = 0.038), while similar correlation was not found in the PUVA-therapy group (mSWAT (<italic>R</italic> = –0.24; <italic>p</italic> = 0.527); BSA (<italic>R</italic> = –0.09; <italic>p</italic> = 0.823)). When comparing the effectiveness of therapy between the treatment group UV-B-311 nm and PUVA therapy, delta mSWAT and BSA at the 20th procedure, delta mSWAT and BSA after the end of therapy did not have a statistically significant difference between the UVB-311 nm and PUVA groups.</p> <p><bold>Conclusion.</bold> Statistically significant correlation was found between the number of procedures and the effectiveness of therapy In the UV-B-311 nm group. An increase in the number of PUVA therapy procedures (after 20) does not lead to a statistically significant increase in the effectiveness of treatment. Additional research is needed to increase the level of evidence of the results and develop optimal phototherapy regimens.</p> <p> </p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Существует необходимость оптимизации применения УФВ-311 нм и ПУВА-терапии у больных грибовидным микозом — определение продолжительности курса, количества сеансов в неделю и режима дозирования облучения.</p> <p><bold>Цель исследования.</bold> Оценка влияния вида и продолжительности фототерапии на ее эффективность у больных грибовидным микозом.</p> <p><bold>Методы.</bold> Сравнительное нерандомизированное исследование эффективности фототерапии у больных грибовидным микозом на ранних стадиях. Оценка эффективности УФВ-311 нм и ПУВА-терапии проводилась с использованием индекса BSA (площадь поражения кожных покровов) и модифицированной шкалы оценки тяжести поражения кожи mSWAT, а также по критериям, предложенным Международным обществом по лимфомам кожи (ISCL), Европейской организации по изучению и лечению рака (EORTC) и Американским консорциумом по кожным лимфомам (USCLC).</p> <p><bold>Результаты.</bold> В исследование включены 14 больных грибовидным микозом, 5 из которых получали лечение УФВ-311 нм, 9 — ПУВА-терапию. Выявлена сильная корреляционная связь между продолжительностью терапии УФВ-311 нм с дельтой mSWAT (<italic>R</italic> = 0,90; <italic>p</italic> = 0,038) и дельтой BSA (<italic>R</italic> = 0,90; <italic>p</italic> = 0,038), в то время как в группе ПУВА-терапии подобной связи обнаружено не было (mSWAT (<italic>R</italic> = –0,24; <italic>p</italic> = 0,527); BSA (<italic>R</italic> = –0,09; <italic>p</italic> = 0,823)). При сравнении эффективности терапии между группой лечения УФВ-311 нм и ПУВА-терапии, дельта mSWATи BSA к 20-й процедуре, дельта mSWATи BSA после завершения терапии статистически значимо не различались между группами УФВ-311 нм и ПУВА.</p> <p><bold>Заключение.</bold> В группе УФВ-311нм выявлена статистически значимая взаимосвязь между числом процедур и эффективностью терапии. Увеличение числа процедур ПУВА-терапии (после 20) не приводит к статистически значимому увеличению эффективности лечения. Необходимо проведение дополнительных исследований, что позволит повысить уровень доказательности результатов и разработать оптимальные режимы фототерапии.</p> <p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>T-cell skin lymphoma</kwd><kwd>mycosis fungoides</kwd><kwd>PUVA therapy</kwd><kwd>UV-B-311 nm</kwd><kwd>phototherapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Т-клеточная лимфома кожи</kwd><kwd>грибовидный микоз</kwd><kwd>ПУВА-терапия</kwd><kwd>УФВ-311 нм</kwd><kwd>фототерапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Olek-Hrab K, Silny W, Dańczak‐Pazdrowska A, et al. Ultraviolet A1 phototherapy for mycosis fungoides. Clin Exp Dermatol 2013 Mar; 38(2):126–30. PMID: 23082901. doi: 10.1111/ced.12001</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Adışen E, Tektaş V, Erduran F, et al. Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides. Dermatology 2017;233:192–198. PMID: 28441652. doi: 10.1159/000458149</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Fujii M, Uehara J, Honma M, et al. Primary cutaneous cd-T-cell lymphoma treated with low-dose methotrexate and narrowband ultraviolet B irradiation: report of a case with testicular involvement. J Dermatol 2011;38:368–372.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of Narrowband UV-B With Psoralen–UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides. A Systematic Review and Meta-analysis. JAMA Dermatol 2019. Published online January 30, 2019. doi:10.1001/jamadermatol.2018.5204. PMID:30698622</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Olsen EA, Whittaker S, Kim YH, et al. International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–2607. doi:10.1200/JCO.2010.32.0630</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The severity-weighted assessment tool (SWAT) Arch Dermatol. 2002;138:42–48.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Перечень редких (орфанных) заболеваний. https://minzdrav.gov.ru/documents/8048</mixed-citation></ref></ref-list></back></article>
